Glucagon and GLP-1 receptor co-agonist
Mazdutide 3 mg subcutaneous once weekly
MAZD_SC_3MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.65 (0.01 to 46.29) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.32 (0.20 to 82.18) | 0.27 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.24 (0.00 to 7.04) | 0.71 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.48 (0.08 to 1.91) | 0.72 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.34 (0.00 to 10.55) | 0.75 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.26 (0.99 to 4.89) | 0.56 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.02 (0.66 to 5.89) | 0.58 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.44 (2.16 to 9.09) | 0.13 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.87 (0.05 to 13.85) | 0.47 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.88 (0.05 to 14.84) | 0.48 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.70 (0.01 to 52.88) | 0.50 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -4.07 (-13.48 to 6.37) | 0.51 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -6.93 (-14.24 to 1.52) | 0.43 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 13.31 (1.27 to 54.56) | 0.55 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 8.00 (1.04 to 52.62) | 0.50 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 5.00 (0.73 to 42.06) | 0.38 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.15 (0.07 to 14.56) | 0.50 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.41 (0.01 to 16.58) | 0.73 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.71 (1.29 to 12.54) | 0.48 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.02 (0.82 to 12.89) | 0.61 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.32 (0.50 to 3.38) | 0.66 |
Trials
- NCT04965506A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes2021 · 252 randomized · 20 weeks
- NCT04904913A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese Subjects2021 · 248 randomized · 24 weeks
- NCT04466904A Multiple Dose Human Tolerability and Pharmacokinetic Study of IBI362 in Chinese Patients With Type 2 Diabetes Mellitus and Poor Glycemic Control2020 · 43 randomized · 12 weeks